Clinical trials
Cetuximab clinical trials
Below are recruiting cetuximab clinical trials, each written for real people, not researchers. We’re tracking 124 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06915142RecruitingPhase 2
Study of HRS-7058 combined with cancer drugs for advanced solid tumors
This trial tests a new drug, HRS-7058, combined with other anti-cancer drugs for people with advanced solid tumors that cannot be surgically removed. The goal is to see if the combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT05410145RecruitingPhase 1/Phase 2
Study drug for advanced KRAS G12C solid tumors
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
Orange, CaliforniaAges 18 years+ - NCT06005324RecruitingPhase 1
Personalized treatment for advanced head and neck cancer
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
Chicago, IllinoisAges 18 years+ - NCT06332170RecruitingPhase 1
HS-20093 combination safety study for advanced solid tumors
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07030959RecruitingPhase 1
AUBE00 for advanced solid tumors with KRAS mutation
This trial tests an experimental drug called AUBE00 for people with solid tumors that have a KRAS mutation, after other treatments have failed. It aims to see if the drug is safe and can shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT05863195RecruitingPhase 3
Pump chemotherapy plus standard chemo for liver-only colorectal spread
This study tests adding a chemotherapy “pump” directly into the liver along with standard chemotherapy, compared with standard chemotherapy alone. It’s for adults with colorectal cancer that has spread to the liver but cannot be surgically removed, and who are responding to first chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT07397338RecruitingPhase 1/Phase 2
RAS inhibitors with ivonescimab for solid tumors
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05382559RecruitingPhase 1
Study drug for advanced cancers with KRAS G12D mutation
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Duarte, CaliforniaAges 18 years+ - NCT07252739RecruitingPhase 2
Study of pembrolizumab plus MK-1084 for KRAS G12C lung cancer
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. The goal is to see if the combination works better than current treatments.
Clermont, FloridaAges 18 years+ - NCT07724223RecruitingPhase 2
Combination targeted therapy for advanced colorectal cancer
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06179160RecruitingPhase 1
Study of INCB161734 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Glendale, ArizonaAges 18 years+ - NCT07318805RecruitingPhase 1
A study of PF-08032562 for advanced solid tumors
This study tests a new medicine, PF-08032562, for people with advanced breast or colorectal cancer that has not responded to prior treatments. It aims to see if the drug is safe and can help shrink or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT04722523RecruitingPhase 1
Cemiplimab plus chemo and other immune treatment for head and neck cancer
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
Basking Ridge, New JerseyAges 18 years+ - NCT07468071RecruitingPhase 1/Phase 2
Continuing opnurasib treatment for patients who are benefiting
This trial allows people who are already taking opnurasib in another Novartis study and seeing good results to keep receiving it. The goal is to let them continue treatment without interruption.
Sint-Niklaas, Oost VlaanderenAges 18–100 - NCT04485013RecruitingPhase 1
Study drug TTX-080 for advanced colorectal cancer
This Phase 1 study tests TTX-080, a drug designed to block a cancer immune “signal” (HLA-G) to help the body fight advanced colorectal cancer. It mainly checks safety and how the treatment works in people with cancer that has spread.
Tucson, ArizonaAges 18 years+ - NCT04687631RecruitingPhase 3
Study drug for colorectal cancer that spread to the liver
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Birmingham, AlabamaAges 18 years+ - NCT05355701RecruitingPhase 1
Testing a new drug for advanced cancers with BRAF changes
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
Fayetteville, ArkansasAges 16 years+ - NCT05628038RecruitingPhase 2
Radiation plus immunotherapy for recurrent rectal cancer
This Phase 2 trial tests whether giving targeted radiation and an immunotherapy drug together can control locally recurring rectal cancer in the pelvis. It may help shrink tumors and slow disease growth, especially after certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05725200RecruitingPhase 2
Personalized treatment plan for metastatic colon or rectal cancer
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
OsloAges 18 years+ - NCT05745857RecruitingPhase 2
Scan for early esophagus cancer using infused antibody dyes
This Phase 2 study uses special drug dyes (bevacizumab and cetuximab, each tagged for imaging) during an esophagus scope to help doctors find very early abnormal cells, like low- or high-grade pre-cancer and superficial cancer. If you qualify, the goal is earlier detection and better targeting during diagnosis and treatment.
Groningen, Provincie GroningenAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Gilbert, ArizonaAges 18 years+ - NCT05956821RecruitingPhase 1/Phase 2
Study drug for young people with recurring brain glioma
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
Miami, FloridaAges 1–21
Hear when a new Cetuximab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cetuximab?
- Yes. Clin2 currently lists 124 recruiting cetuximab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cetuximab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cetuximab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.